CagriSema is a combination therapy of cagrilintide and semaglutide, designed for the treatment of type 2 diabetes and obesity. It is administered as a once-weekly injection and has shown significant results in clinical trials.
CagriSema works by reducing hunger and increasing feelings of fullness, making it effective for weight management
